Abstract
Objective
Describe abobotulinumtoxinA (aboBoNT-A) dosing parameters in the real-world management of lower limb spasticity (LLS).
Methods
Prospective, observational study (NCT04050527) following ambulatory adults with unilateral LLS treated with aboBoNT-A.
Results
The effectiveness population included 384 adults with LLS. The median total injected dose of aboBoNT-A was 600U [range 100–1475U], which was injected into a median of 4 muscles [range 1–8]. Across cycles 1 to 5, the most frequently injected lower limb muscles were the gastrocnemius medial (median of 100–150U injected in up to 84% of patients per cycle) and lateral (100–150U in up to 74%) heads, soleus (200U in up to 67%), tibialis posterior (150–200U in up to 50%), flexor digitorum longus (100–137.5U in up to 41%), and flexor hallucis longus (100U in up to 22%). Other lower limb muscles were injected in fewer than 15% of patients.
Conclusions
In this routine practice study, 6 muscles were identified as being most frequently injected for LLS. Injection practice was consistent with treatment of foot equinus and/or varus as the most common lower limb spasticity patterns. On average, total aboBoNT-A doses for the lower limb muscles were lower than approved.
Describe abobotulinumtoxinA (aboBoNT-A) dosing parameters in the real-world management of lower limb spasticity (LLS).
Methods
Prospective, observational study (NCT04050527) following ambulatory adults with unilateral LLS treated with aboBoNT-A.
Results
The effectiveness population included 384 adults with LLS. The median total injected dose of aboBoNT-A was 600U [range 100–1475U], which was injected into a median of 4 muscles [range 1–8]. Across cycles 1 to 5, the most frequently injected lower limb muscles were the gastrocnemius medial (median of 100–150U injected in up to 84% of patients per cycle) and lateral (100–150U in up to 74%) heads, soleus (200U in up to 67%), tibialis posterior (150–200U in up to 50%), flexor digitorum longus (100–137.5U in up to 41%), and flexor hallucis longus (100U in up to 22%). Other lower limb muscles were injected in fewer than 15% of patients.
Conclusions
In this routine practice study, 6 muscles were identified as being most frequently injected for LLS. Injection practice was consistent with treatment of foot equinus and/or varus as the most common lower limb spasticity patterns. On average, total aboBoNT-A doses for the lower limb muscles were lower than approved.
| Original language | English |
|---|---|
| Article number | 10.2340/jrm.v57.42605 |
| Pages (from-to) | 1-7 |
| Number of pages | 7 |
| Journal | JOURNAL OF REHABILITATION MEDICINE |
| Early online date | 8 Feb 2025 |
| Publication status | Published - 8 Feb 2025 |
Keywords
- abobotulinumtoxinA; botulinum toxin A; goal attainment scaling; rehabilitation